Suresh S Ramalingam
Overview
Explore the profile of Suresh S Ramalingam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
371
Citations
24194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garassino M, He Y, Ahn M, Orlov S, Potter V, Kato T, et al.
Lung Cancer
. 2025 Mar;
202:108417.
PMID: 40056874
Introduction: This post-hoc analysis of the registrational FLAURA study and AURA program reports long-term safety data in epidermal growth factor receptor-mutated (EGFRm), advanced non-small cell lung cancer (NSCLC) treated with...
2.
Hummel H, Ahn M, Blackhall F, Reck M, Akamatsu H, Ramalingam S, et al.
Adv Ther
. 2025 Mar;
PMID: 40025391
Introduction: Tarlatamab demonstrated a durable response and promising survival outcomes in patients with previously treated small cell lung cancer (SCLC) in the phase 2, open-label DeLLphi-301 trial. Patient-reported outcomes (PROs)...
3.
Gridelli C, Mok T, Janne P, Passaro A, Felip E, Ramalingam S, et al.
Lung Cancer
. 2025 Feb;
201:108100.
PMID: 39986216
Background: The front-line treatment options and regulatory approval scenario for epidermal growth factor receptor (EGFR) mutation positive metastatic non-small cell lung cancer (NSCLC) have rapidly evolved in the recent months,...
4.
Reuss J, Zaemes J, Gandhi N, Walker P, Patel S, Xiu J, et al.
Lung Cancer
. 2025 Feb;
200:108101.
PMID: 39924254
Background: Next-generation sequencing (NGS) to detect actionable genomic driver alterations (AGAs) is critical to appropriate management of non-small cell lung cancer (NSCLC), but is inconsistently performed for squamous NSCLC (sqNSCLC)....
5.
Obeng R, Nasti T, Martens K, Li P, Mariniello A, Chang D, et al.
BMJ Oncol
. 2025 Jan;
3(1):e000328.
PMID: 39886145
Objective: Immune checkpoint inhibitors (ICI) that block the programmed cell death 1 (PD-1) pathway have shown promise with limited benefit. We and others have shown in small patient cohorts that...
6.
Zhou F, Guo H, Xia Y, Le X, Tan D, Ramalingam S, et al.
Nat Rev Clin Oncol
. 2024 Nov;
22(2):95-116.
PMID: 39614090
The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation...
7.
Ahn M, Cho B, Felip E, Korantzis I, Ohashi K, Majem M, et al.
Future Oncol
. 2024 Nov;
20(40):3355-3364.
PMID: 39530627
What Is This Summary About?: This is a summary of a phase 2 clinical study called DeLLphi-301. The study looked at how effective and safe a medicine called tarlatamab was...
8.
Tripathi B, Hirsh N, Qian X, Durkin M, Wang D, Papageorge A, et al.
Nat Cancer
. 2024 Nov;
5(12):1902-1918.
PMID: 39528835
Canonical RAS signaling, including PI3K/AKT- and RAF/MEK-dependent activities, results mainly from RAS•GTP interaction with its effectors at the plasma membrane. Here, we identified a fundamental, oncogenic, noncanonical RAS•GTP activity that...
9.
Carlisle J, Pentz R, Ramalingam S
J Thorac Oncol
. 2024 Nov;
19(11):1509-1511.
PMID: 39510705
No abstract available.
10.
Cai S, Hu T, Venkataraman A, Moctezuma F, Ozturk E, Zhang N, et al.
Nat Biomed Eng
. 2024 Oct;
PMID: 39478233
Protein-protein interactions (PPIs) regulate signalling pathways and cell phenotypes, and the visualization of spatially resolved dynamics of PPIs would thus shed light on the activation and crosstalk of signalling networks....